VIRX vs. JAN, IPA, BOLT, SPRB, APLM, RNXT, ENLV, APRE, PMN, and ONCT
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include JanOne (JAN), ImmunoPrecise Antibodies (IPA), Bolt Biotherapeutics (BOLT), Spruce Biosciences (SPRB), Apollomics (APLM), RenovoRx (RNXT), Enlivex Therapeutics (ENLV), Aprea Therapeutics (APRE), ProMIS Neurosciences (PMN), and Oncternal Therapeutics (ONCT). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 6.3% of JanOne shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by company insiders. Comparatively, 3.0% of JanOne shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Viracta Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, JanOne has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.
JanOne has higher revenue and earnings than Viracta Therapeutics.
Viracta Therapeutics received 27 more outperform votes than JanOne when rated by MarketBeat users.
Viracta Therapeutics currently has a consensus target price of $6.50, suggesting a potential upside of 777.79%. Given Viracta Therapeutics' higher probable upside, research analysts plainly believe Viracta Therapeutics is more favorable than JanOne.
Viracta Therapeutics' return on equity of -244.68% beat JanOne's return on equity.
In the previous week, Viracta Therapeutics had 1 more articles in the media than JanOne. MarketBeat recorded 5 mentions for Viracta Therapeutics and 4 mentions for JanOne. JanOne's average media sentiment score of 0.55 beat Viracta Therapeutics' score of 0.42 indicating that JanOne is being referred to more favorably in the news media.
Summary
Viracta Therapeutics beats JanOne on 7 of the 12 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
